Indefinite Delivery Contract SPE2DR25D9156

The Defense Logistics Agency (DLA) awarded a single-award Indefinite Delivery Contract (IDC) to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide a comprehensive range of pharmaceutical products and medical supplies to support the recurring medical needs of military healthcare facilities and veterans' medical centers nationwide. The $499,999,999 IDC, valid through November 2026, covers an extensive portfolio of branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various product categories such as injections, tablets, creams, auto-injectors, and specialty medications.

This IDC was awarded under the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) procurement, which aims to establish multiple regional prime vendor contracts to provide worldwide pharmaceutical support to Department of Defense (DoD) customers, the U.S. Coast Guard, and other government agencies. The solicitation, expected to be issued in March 2024, will be an unrestricted, lowest price technically acceptable acquisition with a 30-month base period and three 30-month option periods, valued at an estimated $30.3 billion in total. The contract will ensure pharmaceutical supply chain resilience by having at least three different regional primary suppliers as well as a dedicated backup supplier.